Oxford Biomedica

Today, we are pleased to announce that Laurence Espinasse, General Counsel at Institut Mérieux joined our Board as a Non-Executive Director on 24th July. Laurence has significant expertise across the legal and healthcare sectors and an impressive track record with more than 20 years of experience working in corporate law, contract law and compliance/risks. Welcome to OXB, Laurence! Read the press release here: https://lnkd.in/dQurEkcX #BoardOfDirectors #CorporateGovernance #CDMO #ViralVectors #CellAndGeneTherapy

Opened in 2021, Oxbox is our largest UK manufacturing facility spanning 84,000 sq. ft. This impressive facility is located on the outskirts of Oxford and contains 45,000 sq. ft. of MHRA approved commercial manufacturing space with 4 GMP vector production suites and 2 fill finish suites. Oxbox also houses supporting areas such as warehousing, cold chain facilities, QC laboratories and fallow area to support future expansion plans. If you’re looking for a CDMO to support you with your viral vector development needs, why not come and visit us? Email partnering@oxb.com to schedule a tour. #CDMO #ViralVectors #GMP #Manufacturing #CellAndGeneTherapies #AdvancedTherapies #Lenti #AAV #Adeno

This morning, we announced the appointment of Lucinda Crabtree, PhD as Chief Financial Officer and Board Member following Stuart Paynter’s decision to step down. We thank Stuart for his dedicated service to OXB over the past 7 years and look forward to welcome Lucinda to OXB on 2 September 2024 when these changes become effective. #CFO #Executive #Appointment #CDMO #Leadership Read more here: https://lnkd.in/dZaAEP7w

We would like to congratulate Google DeepMind who won the very prestigious MacRobert Award last week - the UK's premier prize for engineering innovation. We are delighted that the University of Oxford and AstraZeneca made it to the final of this prestigious award in recognition for the innovative vaccine manufacturing process which was globally rolled out during the COVID-19 pandemic. We are very proud to have been part of this consortium that led to over 3 billion doses of COVID-19 vaccine being distributed, saving millions of lives. #MacRobertAward #EngineeringExcellence #EngineeringInnovation #CDMO #Vaccines https://lnkd.in/deY73fpD

As a global company with facilities in the UK, US and France, we prioritise staying connected and informed so that we can operate seamlessly as One OXB. Last week, our global leaders gathered in the picturesque surroundings of Oxfordshire for an offsite event filled with engaging workshops, insightful discussions, and team-building activities. At OXB, such events provide invaluable opportunities for making sure we remain committed to delivering life-saving therapies to patients by fostering an environment where collaboration, knowledge sharing and intrapreneurship can thrive. #Leadership #Collaboration #TeamBuilding #CDMO #CellAndGeneTherapy

Discover our proven LentiVector® platform technology to rapidly bring your lentiviral vector therapy to market in our new fact sheet available to download on our website at www.oxb.com. Benefit from our expertise and innovative technologies to deliver your gene therapy with improved quality, safety and scalability. Email partnering@oxb.com to learn more. Click here to view our new factsheet: https://lnkd.in/eHfFfzHR #LentiViralVectors #CDMO #CellAndGeneTherapy #ViralVectors

Check out our latest publication in Frontiers in Bioengineering and Biotechnology, in collaboration with University College London (UCL). Our team have identified a class of biomolecules that accumulate during viral vector manufacturing processes, adversely affecting transfection performance. At OXB, we have developed a strategy to selectively target and degrade these inhibitory molecules, enhancing transfection performance and lentiviral vector production. #CDMO #Innovation #CellAndGeneTherapy #ViralVectors #LentiviralVectors

Thank you Pharma's Almanac for the opportunity to participate in your latest roundtable about current investment trends in the pharmaceutical industry. Our Head of Marketing & Strategy, Juergen Nerlich, shared his insights. Here is a quick summary: 🔹De-globalisation to de-risk supply chains 🔹Investment in innovative modalities such as cell therapies and mRNA-based treatments 🔹Investment in strategic technology to enhance manufacturing platforms for better efficiency and scalability  🔹Capacity expansion to meet growing demand 🔹Digitalisation to improve operational efficiencies To learn more, read Juergen’s full response in the link below. What other investment trends do you see as shaping our industry? Please add your thoughts in the comments section below. #ViralVectors #CDMO #CellAndGeneTherapy

Our end-to-end viral vector manufacturing service offering is designed to offer you maximum flexibility. With a vector agnostic offering and different collaboration options, we are ready to support you wherever you’re at in your development journey. To discover more about our flexible development and manufacturing services email partnering@oxb.com to schedule a meeting with a member of our BD team. #CDMO #AdvancedTherapies #ViralVectors #CellAndGeneTherapy